NR546 CEA Comprehensive Exam Prep Document |
2026/2027 Edition | 150 Verified Questions - 150 Questions
with Answers
NR546 CEA Comprehensive Exam 2026-150 QUESTIONS AND CORRECT ANSWERS ALREADY GRADED A+.
100% Verified Solutions | Updated Per Latest Guidelines | Graded A+
This comprehensive exam preparation document is meticulously designed for PMHNP students at
Chamberlain University, focusing on advanced psychopharmacology. It contains 150 verified
questions with correct answers and rationales, covering all major areas of the NR546 curriculum. The
content is updated for the 2026/2027 academic year, ensuring alignment with current evidence-based
practice and guidelines. Ideal for final exam readiness, this resource provides a thorough review of
psychopharmacological principles, clinical applications, and patient management strategies.
Key Features:
Neurobiology and pathophysiology of psychiatric disorders
Pharmacokinetics and pharmacodynamics of psychotropic medications
Antidepressants: SSRIs, SNRIs, TCAs, MAOIs, and atypical agents
Antipsychotics: typical, atypical, and long-acting injectables
Mood stabilizers: lithium, valproate, lamotrigine, and others
Anxiolytics and hypnotics: benzodiazepines, buspirone, and non-benzodiazepine hypnotics
Stimulants and non-stimulants for ADHD
Medications for substance use disorders
Special populations: pediatric, geriatric, pregnancy, and comorbid conditions
Prescribing practices, monitoring, and management of adverse effects
Drug interactions and pharmacogenomics
Patient education and adherence strategies
Ethical and legal considerations in psychopharmacology
Evidence-based treatment guidelines and algorithms
Clinical case scenarios and decision-making
Comprehensive review of all NR546 course objectives
Updates for 2026:
- Updated to reflect 2026/2027 DSM-5-TR and APA guidelines
- Incorporated latest FDA approvals and black box warnings
- Enhanced rationales with current evidence-based research
- Added new questions on emerging pharmacotherapies
- Revised to align with Chamberlain University NR546 course updates
Abstract:
This exam preparation guide offers an exhaustive review of advanced psychopharmacology for the PMHNP,
specifically tailored to the NR546 comprehensive exam at Chamberlain University. It integrates foundational
neuroscience with clinical psychopharmacology, covering all major drug classes, mechanisms of action,
indications, side effects, and monitoring parameters. The content emphasizes evidence-based prescribing,
patient-centered care, and safety considerations across diverse populations. Each of the 150 questions is
accompanied by a detailed rationale, explaining both correct and incorrect options to reinforce learning. The
document is structured to mirror the exam blueprint, ensuring comprehensive coverage of all tested domains.
Updated for the 2026/2027 academic year, it serves as an indispensable tool for achieving a high score and
Page 1
,demonstrating clinical competence in psychopharmacology.
Keywords:
NR546, PMHNP, Psychopharmacology, Comprehensive Exam, Chamberlain University, Verified Questions,
Rationales, 2026/2027
Answer Format:
Each question is followed by the correct answer and a thorough rationale explaining why it is correct, along with
explanations of why the other options are incorrect. This format enhances understanding and retention, preparing
students for the exam's application-based questions.
Compliance Checklist:
Aligns with Chamberlain University NR546 course objectives
Updated to 2026/2027 academic year standards
Includes 150 verified questions with rationales
Covers all major psychopharmacological domains
Suitable for final exam preparation and review
Content Area Overview:
Content Area Questions Key Topics Weight
Foundations of 1-20 Neurobiology, pharmacokinetics, 13%
Psychopharmacology pharmacodynamics, drug interactions
Antidepressants 21-40 SSRIs, SNRIs, TCAs, MAOIs, atypical 13%
antidepressants
Antipsychotics 41-60 Typical, atypical, long-acting injectables, 13%
side effect management
Mood Stabilizers 61-75 Lithium, valproate, lamotrigine, other 10%
anticonvulsants
Anxiolytics and Hypnotics 76-90 Benzodiazepines, buspirone, 10%
non-benzodiazepine hypnotics
ADHD Medications 91-105 Stimulants, non-stimulants, alpha-2 agonists 10%
Substance Use Disorder 106-115 Opioid use disorder, alcohol use disorder, 7%
Medications nicotine cessation
Special Populations 116-130 Pediatric, geriatric, pregnancy, comorbid 10%
medical conditions
Clinical Management and 131-150 Monitoring, adverse effects, patient 14%
Prescribing education, ethical/legal issues
Page 2
,Q1. A patient with treatment-resistant depression is being considered for
augmentation with a second-generation antipsychotic. Which pharmacodynamic
property most distinguishes lurasidone from other atypical antipsychotics in this
context?
A. Full D2 antagonism without partial agonism
B. High affinity for 5-HT7 receptors and negligible H1 antagonism
C. Potent M1 muscarinic antagonism
D. Irreversible MAO-A inhibition
Correct Answer: B. High affinity for 5-HT7 receptors and negligible H1 antagonism
Rationale: Lurasidone uniquely combines potent 5-HT7 antagonism with minimal
histaminergic and muscarinic antagonism, contributing to its favorable metabolic and
cognitive profile. Full D2 antagonism is shared by many atypicals; M1 antagonism is
more characteristic of olanzapine or clozapine; MAO inhibition is not a property of this
class.
Why Wrong:
A - Full D2 antagonism is not unique to lurasidone; most atypical antipsychotics
exhibit this property.
C - Potent M1 muscarinic antagonism is more associated with olanzapine and
clozapine, not lurasidone.
D - MAO-A inhibition is not a property of any second-generation antipsychotic.
Reference: Stahl, S.M. (2021). Stahl's Essential Psychopharmacology, 5th Ed., Ch. 5
Q2. In a patient stabilized on fluoxetine 60 mg daily, which change in CYP450
enzyme activity would most likely necessitate a dose reduction of aripiprazole if
added?
A. CYP2D6 inhibition
B. CYP3A4 induction
C. CYP1A2 inhibition
D. CYP2C19 induction
Correct Answer: A. CYP2D6 inhibition
Rationale: Fluoxetine is a potent CYP2D6 inhibitor, and aripiprazole is a substrate of
CYP2D6; concurrent use increases aripiprazole levels, often requiring dose reduction.
CYP3A4 induction would decrease levels; CYP1A2 and CYP2C19 are not major pathways
for aripiprazole metabolism.
Why Wrong:
B - CYP3A4 induction would decrease aripiprazole concentrations, not increase them.
C - CYP1A2 is not the primary metabolic pathway for aripiprazole.
D - CYP2C19 induction is not a major interaction pathway for aripiprazole.
Page 3
, Reference: Lehne, R.A. (2026). Pharmacology for Nursing Care, 12th Ed., Ch. 3
Q3. Which receptor profile best explains the propensity of quetiapine to cause
orthostatic hypotension at low doses?
A. High D2 occupancy
B. Strong alpha-1 adrenergic antagonism
C. Potent 5-HT2A antagonism
D. Partial D2 agonism
Correct Answer: B. Strong alpha-1 adrenergic antagonism
Rationale: Quetiapine has potent alpha-1 adrenergic antagonism, which causes
vasodilation and orthostatic hypotension even at low doses due to rapid receptor binding.
D2 occupancy is low at low doses; 5-HT2A antagonism contributes to efficacy but not
hypotension; partial D2 agonism is not a property of quetiapine.
Why Wrong:
A - Low D2 occupancy at low doses does not drive hypotension.
C - 5-HT2A antagonism is not the primary cause of orthostatic hypotension.
D - Quetiapine is a D2 antagonist, not a partial agonist.
Reference: Stahl, S.M. (2021). Stahl's Essential Psychopharmacology, 5th Ed., Ch. 5
Q4. A clinician is prescribing a benzodiazepine for a patient with generalized anxiety
disorder who has hepatic impairment (Child-Pugh B). Which agent requires the most
significant dose reduction?
A. Lorazepam
B. Oxazepam
C. Clonazepam
D. Temazepam
Correct Answer: C. Clonazepam
Rationale: Clonazepam is metabolized by hepatic oxidation, which is impaired in liver
disease, leading to prolonged half-life and accumulation. Lorazepam, oxazepam, and
temazepam undergo glucuronidation, which is relatively preserved in hepatic impairment.
Why Wrong:
A - Lorazepam is conjugated and safer in hepatic impairment.
B - Oxazepam also relies on glucuronidation and is safer.
D - Temazepam is also glucuronidated and does not require major dose reduction.
Reference: Lehne, R.A. (2026). Pharmacology for Nursing Care, 12th Ed., Ch. 22
Q5. Which combination of findings would most strongly suggest a diagnosis of
serotonin syndrome rather than neuroleptic malignant syndrome?
A. Hyperthermia, muscle rigidity, and elevated creatine kinase
Page 4
2026/2027 Edition | 150 Verified Questions - 150 Questions
with Answers
NR546 CEA Comprehensive Exam 2026-150 QUESTIONS AND CORRECT ANSWERS ALREADY GRADED A+.
100% Verified Solutions | Updated Per Latest Guidelines | Graded A+
This comprehensive exam preparation document is meticulously designed for PMHNP students at
Chamberlain University, focusing on advanced psychopharmacology. It contains 150 verified
questions with correct answers and rationales, covering all major areas of the NR546 curriculum. The
content is updated for the 2026/2027 academic year, ensuring alignment with current evidence-based
practice and guidelines. Ideal for final exam readiness, this resource provides a thorough review of
psychopharmacological principles, clinical applications, and patient management strategies.
Key Features:
Neurobiology and pathophysiology of psychiatric disorders
Pharmacokinetics and pharmacodynamics of psychotropic medications
Antidepressants: SSRIs, SNRIs, TCAs, MAOIs, and atypical agents
Antipsychotics: typical, atypical, and long-acting injectables
Mood stabilizers: lithium, valproate, lamotrigine, and others
Anxiolytics and hypnotics: benzodiazepines, buspirone, and non-benzodiazepine hypnotics
Stimulants and non-stimulants for ADHD
Medications for substance use disorders
Special populations: pediatric, geriatric, pregnancy, and comorbid conditions
Prescribing practices, monitoring, and management of adverse effects
Drug interactions and pharmacogenomics
Patient education and adherence strategies
Ethical and legal considerations in psychopharmacology
Evidence-based treatment guidelines and algorithms
Clinical case scenarios and decision-making
Comprehensive review of all NR546 course objectives
Updates for 2026:
- Updated to reflect 2026/2027 DSM-5-TR and APA guidelines
- Incorporated latest FDA approvals and black box warnings
- Enhanced rationales with current evidence-based research
- Added new questions on emerging pharmacotherapies
- Revised to align with Chamberlain University NR546 course updates
Abstract:
This exam preparation guide offers an exhaustive review of advanced psychopharmacology for the PMHNP,
specifically tailored to the NR546 comprehensive exam at Chamberlain University. It integrates foundational
neuroscience with clinical psychopharmacology, covering all major drug classes, mechanisms of action,
indications, side effects, and monitoring parameters. The content emphasizes evidence-based prescribing,
patient-centered care, and safety considerations across diverse populations. Each of the 150 questions is
accompanied by a detailed rationale, explaining both correct and incorrect options to reinforce learning. The
document is structured to mirror the exam blueprint, ensuring comprehensive coverage of all tested domains.
Updated for the 2026/2027 academic year, it serves as an indispensable tool for achieving a high score and
Page 1
,demonstrating clinical competence in psychopharmacology.
Keywords:
NR546, PMHNP, Psychopharmacology, Comprehensive Exam, Chamberlain University, Verified Questions,
Rationales, 2026/2027
Answer Format:
Each question is followed by the correct answer and a thorough rationale explaining why it is correct, along with
explanations of why the other options are incorrect. This format enhances understanding and retention, preparing
students for the exam's application-based questions.
Compliance Checklist:
Aligns with Chamberlain University NR546 course objectives
Updated to 2026/2027 academic year standards
Includes 150 verified questions with rationales
Covers all major psychopharmacological domains
Suitable for final exam preparation and review
Content Area Overview:
Content Area Questions Key Topics Weight
Foundations of 1-20 Neurobiology, pharmacokinetics, 13%
Psychopharmacology pharmacodynamics, drug interactions
Antidepressants 21-40 SSRIs, SNRIs, TCAs, MAOIs, atypical 13%
antidepressants
Antipsychotics 41-60 Typical, atypical, long-acting injectables, 13%
side effect management
Mood Stabilizers 61-75 Lithium, valproate, lamotrigine, other 10%
anticonvulsants
Anxiolytics and Hypnotics 76-90 Benzodiazepines, buspirone, 10%
non-benzodiazepine hypnotics
ADHD Medications 91-105 Stimulants, non-stimulants, alpha-2 agonists 10%
Substance Use Disorder 106-115 Opioid use disorder, alcohol use disorder, 7%
Medications nicotine cessation
Special Populations 116-130 Pediatric, geriatric, pregnancy, comorbid 10%
medical conditions
Clinical Management and 131-150 Monitoring, adverse effects, patient 14%
Prescribing education, ethical/legal issues
Page 2
,Q1. A patient with treatment-resistant depression is being considered for
augmentation with a second-generation antipsychotic. Which pharmacodynamic
property most distinguishes lurasidone from other atypical antipsychotics in this
context?
A. Full D2 antagonism without partial agonism
B. High affinity for 5-HT7 receptors and negligible H1 antagonism
C. Potent M1 muscarinic antagonism
D. Irreversible MAO-A inhibition
Correct Answer: B. High affinity for 5-HT7 receptors and negligible H1 antagonism
Rationale: Lurasidone uniquely combines potent 5-HT7 antagonism with minimal
histaminergic and muscarinic antagonism, contributing to its favorable metabolic and
cognitive profile. Full D2 antagonism is shared by many atypicals; M1 antagonism is
more characteristic of olanzapine or clozapine; MAO inhibition is not a property of this
class.
Why Wrong:
A - Full D2 antagonism is not unique to lurasidone; most atypical antipsychotics
exhibit this property.
C - Potent M1 muscarinic antagonism is more associated with olanzapine and
clozapine, not lurasidone.
D - MAO-A inhibition is not a property of any second-generation antipsychotic.
Reference: Stahl, S.M. (2021). Stahl's Essential Psychopharmacology, 5th Ed., Ch. 5
Q2. In a patient stabilized on fluoxetine 60 mg daily, which change in CYP450
enzyme activity would most likely necessitate a dose reduction of aripiprazole if
added?
A. CYP2D6 inhibition
B. CYP3A4 induction
C. CYP1A2 inhibition
D. CYP2C19 induction
Correct Answer: A. CYP2D6 inhibition
Rationale: Fluoxetine is a potent CYP2D6 inhibitor, and aripiprazole is a substrate of
CYP2D6; concurrent use increases aripiprazole levels, often requiring dose reduction.
CYP3A4 induction would decrease levels; CYP1A2 and CYP2C19 are not major pathways
for aripiprazole metabolism.
Why Wrong:
B - CYP3A4 induction would decrease aripiprazole concentrations, not increase them.
C - CYP1A2 is not the primary metabolic pathway for aripiprazole.
D - CYP2C19 induction is not a major interaction pathway for aripiprazole.
Page 3
, Reference: Lehne, R.A. (2026). Pharmacology for Nursing Care, 12th Ed., Ch. 3
Q3. Which receptor profile best explains the propensity of quetiapine to cause
orthostatic hypotension at low doses?
A. High D2 occupancy
B. Strong alpha-1 adrenergic antagonism
C. Potent 5-HT2A antagonism
D. Partial D2 agonism
Correct Answer: B. Strong alpha-1 adrenergic antagonism
Rationale: Quetiapine has potent alpha-1 adrenergic antagonism, which causes
vasodilation and orthostatic hypotension even at low doses due to rapid receptor binding.
D2 occupancy is low at low doses; 5-HT2A antagonism contributes to efficacy but not
hypotension; partial D2 agonism is not a property of quetiapine.
Why Wrong:
A - Low D2 occupancy at low doses does not drive hypotension.
C - 5-HT2A antagonism is not the primary cause of orthostatic hypotension.
D - Quetiapine is a D2 antagonist, not a partial agonist.
Reference: Stahl, S.M. (2021). Stahl's Essential Psychopharmacology, 5th Ed., Ch. 5
Q4. A clinician is prescribing a benzodiazepine for a patient with generalized anxiety
disorder who has hepatic impairment (Child-Pugh B). Which agent requires the most
significant dose reduction?
A. Lorazepam
B. Oxazepam
C. Clonazepam
D. Temazepam
Correct Answer: C. Clonazepam
Rationale: Clonazepam is metabolized by hepatic oxidation, which is impaired in liver
disease, leading to prolonged half-life and accumulation. Lorazepam, oxazepam, and
temazepam undergo glucuronidation, which is relatively preserved in hepatic impairment.
Why Wrong:
A - Lorazepam is conjugated and safer in hepatic impairment.
B - Oxazepam also relies on glucuronidation and is safer.
D - Temazepam is also glucuronidated and does not require major dose reduction.
Reference: Lehne, R.A. (2026). Pharmacology for Nursing Care, 12th Ed., Ch. 22
Q5. Which combination of findings would most strongly suggest a diagnosis of
serotonin syndrome rather than neuroleptic malignant syndrome?
A. Hyperthermia, muscle rigidity, and elevated creatine kinase
Page 4
